PARN Knockdown in Cell Lines Results in Differential and Cell-Specific Alterations in the Expression of

Nishith Babu1, Dechamma Pandyanda Nanjappa1, Sandra Nazareth2

  • 1Division of Molecular Genetics and Cancer, Nitte University Centre for Science Education and Research (NUCSER), NITTE (Deemed to be University), Deralakatte, Mangaluru, Karnataka, India.

Insights

Poly (A)-specific ribonuclease (PARN) depletion alters cancer-associated mRNA stability differently across cell types. PARN deficiency may not be a significant biomarker, especially in lung cancer.

Area of Science:

  • Molecular Biology
  • Gene Regulation
  • Cancer Research

Background:

  • Ribonucleases (RNases) degrade mRNA, with poly (A)-specific ribonuclease (PARN) crucial for eukaryotic mRNA deadenylation.
  • PARN plays a key role in mRNA stability and has non-conventional functions.
  • Altered RNase activity could impact cancer-associated mRNA stability, potentially varying by cell origin.

Purpose of the Study:

  • To investigate the impact of PARN knockdown on cancer-associated gene expression in different cell lineages.
  • To examine the effects of PARN depletion on lung cancer cell proliferation and apoptosis.

Main Methods:

  • siRNA-mediated knockdown of PARN in lung (NCI-H460, NCI-H522) and kidney (HEK-293) cell lines.
  • Quantitative real-time PCR to analyze post-transcriptional expression of oncogenes and tumor suppressor genes.
  • Assessment of lung cancer cell proliferation and death following PARN depletion.

Main Results:

  • PARN depletion caused cell-specific alterations in oncogene and tumor suppressor gene expression.
  • Tumor suppressor genes consistently downregulated across all tested cell types.
  • Oncogene expression varied: upregulated in HEK-293 cells but mostly downregulated in lung cancer cells.
  • PARN depletion did not affect lung cancer cell proliferation, contradicting prior studies.

Conclusions:

  • PARN deficiency distinctly alters cancer-associated mRNA stability based on cell lineage.
  • PARN may not serve as a significant cancer biomarker, particularly for lung cancer, despite prior therapeutic suggestions.